Investor Overview

Corporate Profile

vTv Therapeutics LLC (vTv) is a clinical-stage pharmaceutical company focused on treating metabolic and inflammatory disorders to minimize their long-term complications and improve the lives of patients. Our mission is to advance clinical drug candidates discovered with our innovative technology into safe and effective medicines.

vTv has an innovative pipeline of first-in-class small molecule clinical and pre-clinical drug candidates for the treatment of a wide range of metabolic and inflammatory disorders such as type 1 diabetes and psoriasis . The company has built its product candidate portfolio through internal discovery and is advancing its product candidates through in-house research and development efforts. The quality of vTv’s product candidate pipeline, scientific team, clinical trial execution and strategic collaborations have enabled it to become a leader in its novel therapeutic targets.

Presentations

Date Title
More >>

Recent News

Date Title
Toggle Summary vTv Therapeutics Announces Issuance of U.S. Patent Covering Methods of Treatment Using TTP399
Claims cover methods of reducing HbA1c and the incidence of hypoglycemia using TTP399 in patients with type 1 diabetes HIGH POINT, N.C. , March 23, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc.  (Nasdaq: VTVT) announced today that the U.S. Patent and Trademark Office has issued a patent with
View HTML
Toggle Summary vTv Therapeutics Announces Initiation of Study Evaluating TTP399’s Potential to Reduce Risk of Diabetic Ketoacidosis in Patients with Type 1 Diabetes
HIGH POINT, N.C. , March 18, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc.  (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and inflammatory diseases, today announced the initiation of a mechanistic study
View HTML
Toggle Summary vTv Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
HIGH POINT, N.C. , March 08, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc.  (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and inflammatory diseases, today announced its participation in the H.C.
View HTML
Toggle Summary vTv Therapeutics Announces 2020 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
Initiation of Mechanistic Study of TTP399 expected during Q1 2021 Announcement of First-Patient First-Visit in Multiple Ascending Dose Phase 1 Study of HPP737 Publication of Phase 2 SimpliciT-1 Results of TTP399 in ADA’s Diabetes Care Journal HIGH POINT, N.C. , Feb.
View HTML
Webcasts
More >>
Upcoming Events
More events are coming soon.

Receive E-mail Alerts

Click here to sign up to receive e-mail alerts whenever vTv Therapeutics Inc. posts new information to the site.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Stock Quote

Data Provided by Refinitiv. Minimum 15 minutes delayed.